Back to Search

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

  • Protocol Number: 201906081
  • Principal Investigator: Van Tine, Brian
  • Cancer Types: Early Phase, Lung

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions